Cryoport Talks Compliance, Biopharma Expansion, and Brexit - Outsourcing-Pharma

November 13, 2018

Securing the clinical supply chain comes down to the notion of ‘compliance’, which is transitioning from a ‘nice to have’ to a ‘need to have,’ says Mark W. Sawicki, Ph.D., Chief Commercial officer of...

Building an unbreakable Chain of Compliance® - BioPharma Dealmakers

November 06, 2018

Regenerative medicine advanced therapies in the form of cell and gene therapies are breaking new ground, providing patients the potential of treatment, reversal or even cure of serious and...

Quality Systems for Regenerative Medicine Delivery; Basic Quality Requirements for Distribution - World Pharma Today

August 20, 2018

The emergence of regenerative medicine as a viable therapy class has created an urgency to review and improve upon the current quality systems distribution standards that are employed in support of...

The Chain of Compliance® - Contract Pharma

June 14, 2018

Chain of Compliance® is vital for the Regenerative Medicine Advanced Therapy (RMAT) market which presents a major opportunity for the industry. In a recent Contract Pharma article, Mark W. Sawicki,...

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC